How the common cold ‘protects against Covid’
Experts believe short-lived immune response triggered by human rhinovirus may ‘block’ the new coronavirus

If a nasty cold has left you feeling bunged up, new research findings may offer some consolation - you could also have greater protection against Covid-19.
Scientists from the MRC-University of Glasgow Centre for Virus Research believe that the human rhinovirus, the usual culprit for the common cold, triggers an “innate immune response” that appears to block the replication of Sars-CoV-2, the virus responsible for the new coronavirus, in cells of the respiratory tract.
This immune response may provide “some level of transient protection” against infection and also reduce the severity of Covid cases, according to the experts.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Study leader Professor Pablo Murcia told BBC Newshour that although the protection gained was “short lived”, mathematical models run by his team indicate that rhinovirus infections are “so widespread that they can help suppress” Covid.
“We observed that when you have high prevalence of rhinovirus, that decreases the number of Covid-19 infections at the population level,” Murcia said.
He added that the next goal is to “understand the mechanisms which underpin these interactions at the molecular level” - a step that could pave the way for the development of new drugs and therapies to fight Covid, which has now killed more than 126,000 people in the UK alone.
The new research supports findings from a similar study conducted last year by experts from University College London and the Francis Crick Institute that also suggested antibodies created by the immune system in response to colds may protect against the new coronavirus.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
The London team found that some study participants had antibodies that “recognised” Sars-CoV-2 even though they had not been infected, says science journal Nature.
Around 5% of the 302 uninfected adult participants had antibodies that recognised the virus, as did more than 60% of subjects aged six to 16 - the demographic in which antibodies to common colds are most common.
Sorcha Bradley is a writer at The Week and a regular on “The Week Unwrapped” podcast. She worked at The Week magazine for a year and a half before taking up her current role with the digital team, where she mostly covers UK current affairs and politics. Before joining The Week, Sorcha worked at slow-news start-up Tortoise Media. She has also written for Sky News, The Sunday Times, the London Evening Standard and Grazia magazine, among other publications. She has a master’s in newspaper journalism from City, University of London, where she specialised in political journalism.
-
Slovenia is ready for its moment in the travel spotlight
The Week Recommends Mountains, lakes, caves and coastline await
-
Trump seeks to cut drug prices via executive order
speed read The president's order tells pharmaceutical companies to lower prescription drug prices, but it will likely be thrown out by the courts
-
'Haiti's crisis is a complex problem that defies solution'
Instant Opinion Opinion, comment and editorials of the day
-
RFK Jr.: A new plan for sabotaging vaccines
Feature The Health Secretary announced changes to vaccine testing and asks Americans to 'do your own research'
-
Five years on: How Covid changed everything
Feature We seem to have collectively forgotten Covid’s horrors, but they have completely reshaped politics
-
HMPV is spreading in China but there's no need to worry
The Explainer Respiratory illness is common in winter
-
Marty Makary: the medical contrarian who will lead the FDA
In the Spotlight What Johns Hopkins surgeon and commentator Marty Makary will bring to the FDA
-
Long Covid: study shows damage to brain's 'control centre'
The Explainer Research could help scientists understand long-term effects of Covid-19 as well as conditions such as MS and dementia
-
FDA OKs new Covid vaccine, available soon
Speed read The CDC recommends the new booster to combat the widely-circulating KP.2 strain
-
Mpox: how dangerous is new health emergency?
Today's Big Question Spread of potentially deadly sub-variant more like early days of HIV than Covid, say scientists
-
What is POTS and why is it more common now?
The explainer The condition affecting young women